Dr. Torsten Gerriet Blum qualified from the University of Göttingen, Germany. He was awarded a Doctor title for his dissertation in 2001 on the prognostic impact of the tyrosine kinase receptor c-Met in breast cancer. After clinical training in Lüneburg and Berlin he was appointed Consultant Physician at the Lungenklinik Heckeshorn within the Helios Klinikum Emil von Behring, Berlin in 2008. Among other fields in respiratory medicine, he is specialized in diagnostics and therapy of thoracic malignancies. He is a steering board member of the German national lung cancer guideline group as well as the clinical lung cancer lead within the Association of German Tumor Centres (the network of the German cancer registries). He is the current Secretary and Head-elect of the Thoracic Oncology Assembly within the European Respiratory Society. He has co-chaired several ERS Task Forces within the scope of quality of care in lung cancer.
His main clinical research interest is the management of patients with lung cancer and other thoracic malignancies. He has published on various diagnostic and therapeutic aspects as well as quality of care within this field.

Mario Silva graduated in Radiology at the University of Parma and completed a research fellowship in Cardio-Pulmonary Imaging at the Beth Israel Deaconess Medical Center in Boston, Harvard Medical School, Massachusetts. Dr Silva is an active researcher in the field of thoracic imaging, including thoracic oncology. His main scientific interests are early diagnosis of lung cancer by screening with low-dose CT and the evolving scenario of medical treatment of pulmonary malignancies. During the 2020 pandemic of SARS-CoV-2 he served in the task force for the development of integrated clinics-radiological management of respiratory triage, at the University Hospital of Parma. He has authored or co-authored over 100 peer-reviewed articles published in international scientific journals, numerous abstracts at international congresses, and published book chapters on thoracic imaging. He is Editor of the book “Tumor Dissemination Pathways – The Thorax” by Springer. He is reviewer for various international scientific journals. He is the “Chest” Lead Section Editor of the European Journal of Radiology, moreover he serves as “Chest” Associate Editor of the British Journal of Radiology, and “Diagnostic Imaging” Section Editor of the Tumori Journal. He is currently Assistant Professor at the University of Parma (Italy).

Mario Silva, MD, PhD
Scienze Radiologiche – Department of Medicine and Surgery (DiMeC)
University of Parma,
Parma, Italy
This email address is being protected from spambots. You need JavaScript enabled to view it.

Professor Oudkerk is professor of Radiology at the University of Groningen, Chief Scientific Officer of the Institute for Diagnostic Accuracy- iDNA (formerly of the Center of Medical Imaging NORTH EAST NETHERLANDS , NWO research Center of Exellence) and the principal investigator for Radiology of the NELSON lung cancer detection study, the ROBINSCA cardiovascular screening study and the 4-in-the-Lungrun Horizon 2020 study. Founder and past president of the European Society of Cardiac Radiology and former Chairman of Radiology departments of DDHK Erasmus MC Rotterdam and University Medical Center Groningen. For his research work he received prestigious grants such as EU Horizon 2020, ERC advanced grant, Royal Academy of Sciences of the Netherlands (KNAW), Ministry of Science and Technology of China (MOST), NWO, KWF, NKB grants etc.Key publications in Nature, NEJM, Lancet, JAMA,Thorax, Circulation, JACC, Eur Heart, Radiology, Lancet Oncology, European Radiology etc.
Many years he chaired the CBO guideline committee on Pulmonary Embolism with Prof Harry Buhler on which topic they published 2 monographies together with prof Edwin van Beek. Recently he chaired the Expert Advisory Group of the National Institute of Public Health on the Thrombo-embolic complications of COVID19 at the moment of the outbreak of the pandemic in the Netherlands. Scopus H-index 78 Citations > 23.000 Publications peer reviewed > 560

Prof.ssa Veronesi is an Associate Professor of Thoracic Surgery at Vita-Salute San Raffaele University and Director of Robotic Thoracic Surgery Program at San Raffaele Hospital in Milan (Italy). She previously headed the Robotic Surgery Unit at the Humanitas Research Hospital in Rozzano (Mi-Italy) and screening and lung cancer prevention unit at European Institute of Oncology.
Degree in Medicine and Surgery from the University of Milan (Italy) in 1994. Specialties in Thoracic Surgery in 2006 University of Modena and Reggio Emilia (Italy), Specialist in Surgery of the digestive system and surgical digestive endoscopy in 2000 University of Milan (Italy).
She has led one of the largest European lung cancer screening programs (COSMOS studies) using low dose tomography and MicroRNA testing in high risk individuals and was principal investigator of several lung cancer chemo prevention trials funded by the American National Cancer Institute including the randomized study on inhaled Budesonide compared to placebo for screen detected lung nodules and the randomized study on the protective role of Aspirin in healthy subjects with subsolid lung lesions.
Since 2007 she has developed a robotic surgery program for oncological chest diseases, she is tutor of robotic surgery in Italy and other European countries.
She has designed and co-ordinated an international multicentre randomized trial to compare robotic and manual videotoroscopic surgery for the treatment of lung cancer and has instituted an European working group within the European Society of Thoracic Surgery (ESTS) on Robotics Surgery focused on training and education.
She won a prize in 2019 of the Robert J. Ginsberg Lectureship Award for Surgery (20th WCLC – Barcellona, Spain) and in 2017 of the Women and Technology Association as a techno-visionary in medicine.
Her academic contributions include more than 240 publications in peer-reviewed indexed international journals (Scopus source : H-index 41, cited 6107) and 5 book chapters.
She is member of the Editorial Board of: Lung Cancer, Annals of Thoracic Surgery, Ecancermedicalscience, Frontiers in Oncology, Journal of Thoracic Disease, Journal of Visualized Surgery. She is Founding Member of Clinical Robotic Surgeon Association and Founder of the European Society of Thoracic Surgeons (ESTS) Robotic Working Group. She is PI of an International European study funded by ERANET.

David Baldwin works as a consultant respiratory physician sub-specialising in lung cancer and mesothelioma and interventional procedures. He is Honorary Professor in the School of Medicine at the University of Nottingham. He is Chair of the National Clinical Expert Group for Lung Cancer and Chair of the Screening Prevention and Early Diagnosis Group for the National Cancer Research Institute. He has obtained research grants from a variety of charities and NIHR. His primary research interests are in CT screening and lung cancer epidemiology. He is leading the novel recruitment work package in the 4-in-the-Lung-Run project. He was lead respiratory physician on the UK CT lung cancer screening trial (UKLS). He has published over 210 papers, including three influential guidelines. He has held the positions of Honorary Secretary of the British Thoracic Society, Clinical Lead on the NICE Lung Cancer Guideline Development Group, Chair of the Quality Standards Group on Lung Cancer and Clinical Director of the East Midlands Cancer Alliance. He enjoys time with his family and is a keen windsurfer and advanced instructor.

Professor Nick Pavlakis is medical oncologist with more than 20 years’ experience in the oncology field, including clinical and translational research. He trained in anti-angiogenic drug development and has an interest in new drug development and evaluation of drug resistance in lung cancer, mesothelioma, and GI malignancies. He is study lead of several national and international co-operative group studies, including overseeing several translational research projects and PhD students. He is a deputy chair of the IASLC CME Committee and has served on Faculty of the WCLC. He is the Board Chair of the new Thoracic Oncology Group of Australasia.

Professor Sanjay Popat is a Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Professor of Thoracic Oncology at the Institute of cancer Research.
His research interests include the development of novel drug strategies for the treatment of thoracic cancers through clinical trials, the identification of DNA variants that influence thoracic cancer development and their impact on clinical behaviour, as well as the identification of biomarkers predictive of therapeutic effect.
He is co-director for the NIHR London South Clinical Research Network (CRN) Cancer Division and Chair of Cancer for the West London Genomic Medicine Centre. He Chairs the British Thoracic Oncology Group (BTOG), and is immediate past Chair of the UK NCRI Lung Cancer Clinical Studies Group (CSG) Advanced Disease Sub-group. He is active in the European Thoracic Oncology Platform (ETOP) and the European Organization for Research and Treatment of Cancer (EORTC) Lung Group.

Mary W. Redman, Ph.D. is a Professor in Clinical Biostatistics in the Clinical Research Division at Fred Hutchinson Cancer Research Center. She has extensive experience in clinical trials, particularly in lung cancer. Dr. Redman has been the lead statistician for the Lung Cancer Committee in the SWOG Cancer Research Network for 15 years and as of 2019, is the head of the Biostatistics Core for the Fred Hutch Lung SPORE. She has extensive experience in phase II and III trials incorporating biomarkers and is the lead statistician for the Lung-MAP Master Protocol, the first of the master protocols launched within the National Clinical Trials Network, and a trial that has served as a model for master protocols and the FDA guidance on master protocols.

Dr. Drezner completed her training in pediatric hematology/oncology at Children's National Medical Center in 2015 where she remained until 2016 to complete a fellowship in pediatric neuro-oncology. She joined the U.S. FDA in 2016 as a clinical reviewer on the Thoracic and Head and Neck Cancer team.